Select a community
Mood Conditions including Depression, Anxiety, Bipolar, OCD, and PTSD
Find out more about the PatientsLikeMe
Mood Conditions Community
Home > Community Treatment Reports > Tenormin (atenolol) Treatment Report
What is Tenormin?

Tenormin®, a brand name for the drug atenonol, is a beta blocker used to treat hypertension, alone or in combination with other agents. Off label use for acute alcohol withdrawal, certain cardiac arrhythmias, and prevention of migraine headache.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken
# of patients Efficacy
Major
Moderate
Slight
None
Can’t tell
# of patients evaluated by
Tachycardia 2 2
High blood pressure (Hypertension) 1 5

See all 2 patients currently taking Tenormin

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
2 17%
Mild
3 25%
None
7 58%

Most commonly reported side effects

Pain in legs
1 25%
weak, tired slow heart rate
1 25%
Cold hands and feet
1 25%
Shortness of breath
1 25%
Dizziness
1 25%
Fatigue
1 25%
  • Mild
  • Moderate
  • Severe

Dosages

  50 mg daily 100 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Tenormin (multiple reasons could be selected)
Reason # Patients Percentage of patients
Personal research
1 100% Personal research: 100%

See all 1 patient who’ve stopped taking Tenormin

Currently Taking Tenormin

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Tenormin

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
10 83%
Usually
2 17%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
1 8%
Somewhat
0 0%
A little
1 8%
Not at all
10 83%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
9 75%

See more information, including instructions, precautions, side effects, and interactions.

Report created on March 12, 2010.